The good news for any holders of GSK (LON:GSK) is that the price is currently trading close to a 52 week high, with the share price up by around 2.45% to 1,737p over the past week. For investors holding the stock (or considering buyin...
GSK — GSK Share Price
0.000.00%
Last trade - 00:00HealthcareConservativeLarge CapNeutral
- £91.65bn
- £117.45bn
- £34.11bn
- 66
- 44
- 97
- 82
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 14.12 | ||
| PEG Ratio (f) | 0.81 | ||
| EPS Growth (f) | 20.98% | ||
| Dividend Yield (f) | 3% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.61 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 13 | ||
| Price to Sales | 2.49 | ||
| EV to EBITDA | 11.67 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 11.12% | ||
| Return on Equity | 32.94% | ||
| Operating Margin | 19.94% | ||
Financial Summary
| Year End 31st Dec | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | 30,186 | 30,821 | 33,754 | 34,099 | 34,114 | 36,600.73 | 37,320.95 | 4.11% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +189.08 | -9.76 | +58.64 | -28.18 | -10.35 | +38.8 | +8.31 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health Trend(F-Score)
12345678910
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Latest News & Insights for GSK
Shares in GlaxoSmithKline (LON:GSK) are currently trading close to a 52 week high, with the share price up by around 0.49% to 1,764p over the past week. On a one-month basis, the GlaxoSmithKline price has risen by 1.33%. For investors...
A question on the minds of many investors right now is how economic uncertainty will continue to affect large cap companies, such as GlaxoSmithKline (LON:GSK). Shares in GlaxoSmithKline are currently trading at 1,764p. But to assess wh...
Shares in Glaxosmithkline (LON:GSK) are currently trading close to a 52 week high, with the share price up by around -1.65% to 1,781p over the past week. On a one-month basis, the Glaxosmithkline price has risen by 4.51%. For investors...
Geopolitical shockwaves and economic uncertainty are causing turmoil this year. Some shares are better able to absorb this kind of disruption than others - but could Glaxosmithkline (LON:GSK) be one of them? To understand why differe...
Profile Summary
GSK plc, formerly GlaxoSmithKline PLC is a global healthcare company. The Company is focused to improve the quality of human life by helping people. The Company operates through three core businesses: Pharmaceuticals, Vaccines and Consumer Healthcare. Its Pharmaceuticals business has a portfolio of established medicines in respiratory, human immunodeficiency viruses (HIV), immuno-inflammation and oncology. It also focuses on immunology, human genetics, and advanced technologies to deliver transformational new medicines for patients. The Company's research and development focuses on developing vaccines against infectious diseases that combine high medical needs and market potential. The Company's Consumer Healthcare business combines science and consumer insights to create everyday healthcare brands for oral health, pain relief, cold, flu and allergy, digestive health, and vitamins, minerals and supplements. It provides prescription medicines, vaccines, and consumer healthcare products.
Directors
- Jonathan Symonds NEC (62)
- Emma Walmsley CEO (52)
- Iain Mackay CFO (60)
- Roger Connor CEX
- Brian McNamara CEX
- Luke Miels CEX
- Regis Simard CEX
- Phil Thomson CEX
- Deborah Waterhouse CEX
- James Ford SVP
- Diana Conrad SVP
- Nick Hirons SVP
- Sally Jackson SVP (51)
- Karenann Terrell CTO (59)
- Hal Barron CSO (58)
- David Redfern OTH (55)
- Tony Wood OTH
- Victoria Whyte SEC
- Charles Bancroft NID (61)
- Marvinder Banga NID (66)
- Anne Beal NID
- Vivienne Cox NID
- Harry Dietz NID
- Lynn Elsenhans NID (64)
- Laurie Glimcher NID (70)
- Jesse Goodman NID (69)
- Judy Lewent NID (72)
- Urs Rohner NID (61)
- Last Annual
- December 31st, 2021
- Last Interim
- March 31st, 2022
- Incorporated
- December 6th, 1999
- Public Since
- May 22nd, 1972
- No. of Shareholders
- 97,570
- No. of Employees
- 90,096
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 5,084,151,821
- Address
- 980 Great West Road, BRENTFORD, TW8 9GS
- Web
- https://www.gsk.com/
- Phone
- +44 2080475000
- Auditors
- Deloitte LLP
Latest News for GSK
Upcoming Events for GSK
GSK plc Ordinary Shareholders Meeting
Q2 2022 GlaxoSmithKline PLC Earnings Release
Dividend For GSK.BA - 0.1225 USD
Q3 2022 GlaxoSmithKline PLC Earnings Release
Similar to GSK
Abcam
London Stock Exchange
Alliance Pharma
London Stock Exchange
Animalcare
London Stock Exchange
AstraZeneca
London Stock Exchange
Benchmark Holdings
London Stock Exchange
FAQ
What is the GSK share price?
As of Today at 07:10 UTC, shares in GSK are trading at 1,785.60p. This share price information is delayed by 15 minutes.
How has the GSK share price performed this year?
Shares in GSK last closed at 1,785.60p and the price had moved by +24.17% over the past 365 days. In terms of relative price strength the GSK share price has outperformed the FTSE All Share Index by +28.14% over the past year.
What are the analyst and broker recommendations for GSK?
The overall consensus recommendation for GSK is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the GSK dividend yield?
The GSK dividend yield is 4.2% based on the trailing twelve month period.
Does GSK pay a dividend?
Last year, GSK paid a total dividend of £0.75, and it currently has a trailing dividend yield of 4.2%. We do not have any data on when GSK is to next pay dividends.
When does GSK next pay dividends?
We do not have data on when GSK is to next pay dividends. The historic dividend yield on GSK shares is currently 4.2%.
How do I buy GSK shares?
To buy shares in GSK you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of GSK?
As of the previous close price of 1,785.60p, shares in GSK had a market capitalisation of £91.65bn.
Where are GSK shares listed?
Here are the trading details for GSK:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: GSK
What kind of share is GSK?
Based on an overall assessment of its quality, value and momentum GSK is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a GSK share price forecast for 2022?
The analyst consensus target price for shares in GSK is 1,788.22p. That is 0.15% above the last closing price of 1,785.60p.
Analysts covering GSK currently have a consensus Earnings Per Share (EPS) forecast of £1.22 for the next financial year.
What is the trend in the GSK share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like GSK. Over the past six months, its share price has outperformed the FTSE All Share Index by +20.62%.
As of the last closing price of 1,785.60p, shares in GSK were trading +11.03% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the GSK PE Ratio?
The GSK PE ratio based on its reported earnings over the past 12 months is 14.12. The shares last closed at 1,785.60p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of GSK?
GSK's management team is headed by:
- Jonathan Symonds - NEC
- Emma Walmsley - CEO
- Iain Mackay - CFO
- Roger Connor - CEX
- Brian McNamara - CEX
- Luke Miels - CEX
- Regis Simard - CEX
- Phil Thomson - CEX
- Deborah Waterhouse - CEX
- James Ford - SVP
- Diana Conrad - SVP
- Nick Hirons - SVP
- Sally Jackson - SVP
- Karenann Terrell - CTO
- Hal Barron - CSO
- David Redfern - OTH
- Tony Wood - OTH
- Victoria Whyte - SEC
- Charles Bancroft - NID
- Marvinder Banga - NID
- Anne Beal - NID
- Vivienne Cox - NID
- Harry Dietz - NID
- Lynn Elsenhans - NID
- Laurie Glimcher - NID
- Jesse Goodman - NID
- Judy Lewent - NID
- Urs Rohner - NID